COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F22%3A43920660" target="_blank" >RIV/00064173:_____/22:43920660 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/22:43920660

Výsledek na webu

<a href="https://doi.org/10.1080/09546634.2020.1822500" target="_blank" >https://doi.org/10.1080/09546634.2020.1822500</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/09546634.2020.1822500" target="_blank" >10.1080/09546634.2020.1822500</a>

Jazyk výsledku

angličtina

Název v původním jazyce

COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma

Popis výsledku v původním jazyce

The COVID-19 pandemic has changed the therapeutic algorithm for many dermatological diseases, particularly those where drugs are influencing the immune system. Patients with advanced melanoma are treated with immunotherapy or targeted therapy in an adjuvant or palliative regimen. There are only a few guidelines suggesting the approach to these patients, many are being treated on an individual basis. According to the National Comprehensive Cancer Network guidelines, initiation of immunotherapy/targeted therapy for metastatic disease or in an adjuvant setting is still recommended during the COVID-19 pandemic. Immune checkpoint blockade activates the immune system by enhancing T-cell proliferation and cytokine production. The extent to which an activated immune response may influence the clinical course of COVID-19 or whether it induces or enhances a hyperinflammatory reaction, is currently unknown. We evaluated 104 patients currently being treated with immunotherapy for advanced melanoma. In 76 patients the therapy was ongoing, while in 28 patients the treatment was initiated during the pandemic. Individuals were treated in an adjuvant or palliative setting with anti-PD-1 monotherapy (nivolumab/pembrolizumab), combo treatment (ipilimumab + nivolumab) or triplet treatment (spartalizumab + dabrafenib + trametinib).

Název v anglickém jazyce

COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma

Popis výsledku anglicky

The COVID-19 pandemic has changed the therapeutic algorithm for many dermatological diseases, particularly those where drugs are influencing the immune system. Patients with advanced melanoma are treated with immunotherapy or targeted therapy in an adjuvant or palliative regimen. There are only a few guidelines suggesting the approach to these patients, many are being treated on an individual basis. According to the National Comprehensive Cancer Network guidelines, initiation of immunotherapy/targeted therapy for metastatic disease or in an adjuvant setting is still recommended during the COVID-19 pandemic. Immune checkpoint blockade activates the immune system by enhancing T-cell proliferation and cytokine production. The extent to which an activated immune response may influence the clinical course of COVID-19 or whether it induces or enhances a hyperinflammatory reaction, is currently unknown. We evaluated 104 patients currently being treated with immunotherapy for advanced melanoma. In 76 patients the therapy was ongoing, while in 28 patients the treatment was initiated during the pandemic. Individuals were treated in an adjuvant or palliative setting with anti-PD-1 monotherapy (nivolumab/pembrolizumab), combo treatment (ipilimumab + nivolumab) or triplet treatment (spartalizumab + dabrafenib + trametinib).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Dermatological Treatment

ISSN

0954-6634

e-ISSN

1471-1753

Svazek periodika

33

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

2

Strana od-do

1782-1783

Kód UT WoS článku

000581153000001

EID výsledku v databázi Scopus

2-s2.0-85093683241